Previous 10 | Next 10 |
Y-mAbs Therapeutics' (NASDAQ:YMAB) humanized anti-GD2 antibody naxitamab, in combination with other oncologics, met its primary endpoint in a phase 2 trial of patients with chemoresistant high-risk neuroblastoma. Objective response rate, the primary endpoint, was 30.6% in a cohort of patients...
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for t...
The following slide deck was published by Y-mAbs Therapeutics, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Y-mAbs Therapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation
Y-mAbs Therapeutics press release (NASDAQ:YMAB): Q1 GAAP EPS of -$0.64 beats by $0.08. Revenue of $10.49M (+94.3% Y/Y) misses by $0.61M. For further details see: Y-mAbs Therapeutics GAAP EPS of -$0.64 beats by $0.08, revenue of $10.49M misses by $0.61M
NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter March 31, 2022 on Monday, May 9, 2022, after the close of the U.S. financial ...
Y-mAbs Therapeutics (NASDAQ:YMAB) said Wednesday CEO Claus Moller stepped down from his role and as board member, effective immediately. Thomas Gad - YMAB's founder, chairman and president - assumed the role of interim CEO and board member. Gad also stepped down as chairman and Jim Healy, cur...
CEO and Board Member Dr. Claus Moller has stepped down; Thomas Gad, Founder, Chairman and President assumes Interim CEO role and steps down as Chairman; Dr. Jim Healy to be appointed as Chairman DANYELZA® first quarter revenues were $10.5 million, up 9% sequentially quarter over ...
Gainers: Spruce Biosciences (SPRB) +7%. ThredUp (TDUP) +7%. Cellectis (CLLS) +6%. Revolution Medicines (RVMD) +5%. Ocular Therapeutix (OCUL) +5%. Losers: Trean Insurance Group (TIG) -7%. Lyell Immunopharma (LYEL) -6%. Vivid Seats (SEAT) -6%. Y-mAbs Therapeutic...
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the t...
Y-mAbs Therapeutics (NASDAQ:YMAB) announced on Friday that it had completed the resubmission of its Biologics License Application for neuroblastoma therapy omburtamab to the U.S. Food and Drug Administration. In Oct. 2020, the agency had issued Refusal to File letter regar...
News, Short Squeeze, Breakout and More Instantly...
Y-mAbs Therapeutics Inc. Company Name:
YMAB Stock Symbol:
NASDAQ Market:
Y-mAbs Therapeutics Inc. Website:
2024-07-05 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic pr...
Q1 2023 DANYELZA® record net product revenues of $20.3 million, driving YoY growth of 93% and a 24% sequential increase compared to Q4 2022 Management updates 2023 financial guidance, now anticipating higher DANYELZA net revenues of $80-85 million and lower cash burn of $40-50 millio...